Transgene Publishes Preclinical Data on Oncolytic Virus TG6050 in JITC

Strasbourg-based biotech company Transgene has announced the publication of preclinical data on TG6050 in the Journal for ImmunoTherapy of Cancer (JITC). The data show that TG6050 induces tumor regression and significant remodeling of the tumor microenvironment in animal models.

TG6050, an oncolytic virus developed using Transgene's invir.IO® platform, encodes interleukin-12 (IL-12) and an anti-CTLA-4 antibody. The study highlights its potential to induce sustained intratumoral expression of these agents without the toxicity typically associated with systemic administration. In addition, TG6050 was found to be safe in non-human primates, showing no adverse effects upon repeated intravenous administration.

Currently, TG6050 is being evaluated in a Phase I clinical trial for metastatic non-small cell lung cancer. The trial aims to determine the optimal dosing and delivery schedule for advanced clinical development.